Trump's Psychedelics Research Order Draws Bipartisan Praise

President Donald Trump's executive order directing federal agencies to accelerate psychedelics research has generated an unusual wave of bipartisan support from lawmakers, health officials, and advocacy groups.

Sen. Lindsey Graham (R-SC) said he "totally supports" the president's move to expand research into therapeutic applications of psychedelic compounds. The order tasks multiple federal agencies with expediting studies on substances like psilocybin and MDMA for treating mental health conditions including PTSD, depression, and addiction.

The directive comes as psychedelics reform has gained momentum at both state and federal levels. Oregon and Colorado voters have already approved regulated psilocybin programs, while cities across the country have decriminalized possession. But federal research has remained constrained by scheduling restrictions—a barrier this order aims to address.

The Political Response

The executive order has drawn support from both sides of the aisle, reflecting growing consensus around psychedelics research even as cannabis policy remains divisive. Several Democratic lawmakers who have championed drug policy reform praised the administration's focus on evidence-based approaches to mental health treatment.

State officials in jurisdictions that have already moved forward with psychedelics reform welcomed the federal coordination. Oregon, which launched the nation's first legal psilocybin program in 2023, could benefit from expanded federal research that validates therapeutic protocols and training standards.

Advocacy organizations that have pushed for psychedelics access, particularly for veterans with PTSD, called the order a critical step. Veterans groups have long argued that psychedelic-assisted therapy shows promise where traditional treatments have failed, pointing to clinical trials showing significant improvements in treatment-resistant conditions.

Industry and Medical Community

The pharmaceutical and psychedelics therapy sectors are watching closely. Several publicly traded companies focused on psychedelic medicine saw stock movement following the announcement, though the order stops short of changing scheduling classifications that would enable broader commercialization.

Medical researchers noted that federal funding and regulatory clarity could accelerate ongoing studies. Current psychedelics research faces lengthy approval processes and limited funding compared to conventional drug development. The order directs agencies to streamline these pathways while maintaining safety standards.

Some celebrity advocates who have spoken publicly about psychedelics and mental health also weighed in, amplifying the message to broader audiences. Their involvement reflects how psychedelics have entered mainstream conversation around mental health treatment in ways that parallel—and sometimes outpace—cannabis normalization.

What Comes Next

The executive order doesn't immediately change drug scheduling or create legal access outside existing state programs. Instead, it establishes a framework for federal agencies to prioritize psychedelics research and remove bureaucratic obstacles.

Federal health agencies now have 90 days to submit plans for expediting clinical trials and expanding research partnerships. The order also calls for coordination with the Department of Veterans Affairs, which has faced pressure to explore psychedelic treatments for service members.

Whether this federal momentum translates to broader policy changes remains uncertain. Unlike cannabis, psychedelics reform hasn't yet become a partisan wedge issue—the bipartisan response to this order suggests it may avoid that fate. But questions about commercialization, regulation, and equitable access will need answers as research advances.

The cannabis industry is watching the psychedelics space closely, seeing both opportunities and cautionary tales. Many cannabis operators have explored psychedelics ventures, while others warn against repeating mistakes from cannabis legalization. How federal policy evolves could shape whether psychedelics follow a medical pathway, a regulated adult-use model, or something entirely different.

This article is based on original reporting by www.marijuanamoment.net.